Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Analyst at Moore Capital Management

<< Previous

Bullboard Posts

Next >>

Post by jeffm34on Jul 30, 2021 7:51pm

244 Views

Post# 33636181

Analyst at Moore Capital Management

There is a biotech equity analyst at Moore Capital Managment in New York. He has a Ph.D. in pharmacology. He did his graduate research on Sortilin and its involvement in LDL metabolism. I'd be curious what insight he might have on TH1902. In particular, potential liver toxicity due to Sortilin expression in hepatocytes.

https://www.linkedin.com/in/kevinmpatel/

https://repository.upenn.edu/cgi/viewcontent.cgi?article=3721&context=edissertations

<< Previous

Bullboard Posts

Next >>

Nextech CEO provides company update on Amazon deal and more